Table 3.
Screen-Detected SCLC and NSCLC Cases (LDCT Arm)
| NCN Characteristic | SCLC |
NSCLC |
||||||
|---|---|---|---|---|---|---|---|---|
| No. (%) | Median Time (d) to Dx | Stage I/II No. (%) | 3-y Survival | No. (%) | Median Time (d) to Dx | Stage I/II No. (%) | 3-y Survival | |
| ≥1 NCN in cancer lobe | 31 (63.3) | 54 | 4 (13.3) | 18.6% | 505 (85.4) | 73 | 394 (78.3) | 80.7% |
| <1 NCN in cancer lobea | 18 (36.7) | 166 | 3 (18.8) | 8.3% | 86 (14.6) | 116 | 42 (50.0) | 56.9% |
| All | 49 | 591 | ||||||
Survival NSCLC ≥ 1 NCN vs other, P < .0001. Stage I/II NSCLC ≥ 1 NCN vs other, P < .0001. Time to Dx, P = .09. Survival SCLC ≥1 NCN vs other, P = .7. Stage I/II SCLC ≥ 1 NCN vs other, P = .63. Time to Dx, P = .054. Percentage with ≥ 1 NCN NSCLC vs SCLC, P < .0001. Nonlobe locations: L,R hilar, L,R main stem bronchus, mediastinum, carina. Dx = diagnosis. See Table 1 and 2 legends for expansion of other abbreviations.
a
Includes the following: (1) no NCNs in cancer lobe (SCLC, 10 [20.4]; NSCLC, 67 [11.3]); (2) non-lobe cancer location (SCLC, 4 [8.1]; NSCLC, 9 [1.5]); and (3) unknown cancer location (SCLC, 4 [8.1]; NSCLC, 10 [1.7]).